#SFHS2609406AFrance expands reimbursement for Olumiant in juvenile arthritis
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This measure expands public reimbursement in France for Olumiant 2 mg and 4 mg tablets. The new covered use is for children age 2 and older with certain forms of juvenile idiopathic arthritis, juvenile psoriatic arthritis, or enthesitis-related arthritis, when prior disease-modifying treatments have not worked or were not tolerated, including at least one anti-TNF when possible. For healthcare providers and payers, the practical effect is broader access to a reimbursed treatment option and a need to apply the updated coverage criteria when prescribing, dispensing, and billing these products.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Extends public reimbursement to Olumiant 2 mg and 4 mg tablets in new pediatric arthritis indications
- Covers children aged 2 years and older with specified juvenile arthritis conditions after inadequate response or intolerance to prior DMARDs
- Requires that at least one anti-TNF treatment be tried when possible before reimbursement applies
Obligations
What this law requires
Public health reimbursement authorities in France must extend reimbursement coverage to Olumiant 2 mg and 4 mg (baricitinib) tablets for treatment of juvenile idiopathic arthritis subtypes listed in the annex: polyarticular JIA (RF+ or RF-), extended oligoarticular JIA, enthesitis-related arthritis, and juvenile psoriatic arthritis, for patients aged 2 years and older who have had an inadequate response to or intolerance of one or more DMARDs, including at least one anti-TNF when possible.
Health insurers and reimbursement administrators in France must apply public reimbursement coverage to OLUMIANT 2 mg and 4 mg (baricitinib) tablets for patients aged 2 years and older when used to treat polyarticular juvenile idiopathic arthritis (RF+ or RF-), extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or juvenile psoriatic arthritis, provided the patient has had an inadequate response or intolerance to one or more DMARDs, including at least one anti-TNF where possible.
Prescribers and hospitals must apply the expanded reimbursement scope only within the specified pediatric rheumatology indications and patient criteria set out in the annex when seeking reimbursement for Olumiant.
Prescribers and dispensing pharmacies must use the updated reimbursement criteria when prescribing and dispensing OLUMIANT 2 mg and 4 mg, limiting reimbursed use to the extended pediatric indications and prior-treatment conditions set out in the annex.
Billing entities must submit claims for OLUMIANT 2 mg and 4 mg only within the reimbursable indication and patient-eligibility criteria specified in the annex to avoid non-covered reimbursement requests.